Show simple item record

A modular, open-label, phase I/II study to evaluate the safety, tolerability, pharmacokinetics and efficacy of EP0031, a next generation selective RET inhibitor, in patients with advanced RET-altered malignancies

dc.contributor.authorGianoukakis, A. G.en
dc.contributor.authorArnold, S. M.en
dc.contributor.authorKahn, S. A.en
dc.contributor.authorTaylor, M.en
dc.contributor.authorGarralda, E.en
dc.contributor.authorKrebs, Matthew Gen
dc.contributor.authorArkenau, H. T.en
dc.contributor.authorClark, L.en
dc.contributor.authorFisher, G.en
dc.contributor.authorSubbiah, V.en
dc.date.accessioned2023-07-05T09:11:08Z
dc.date.available2023-07-05T09:11:08Z
dc.date.issued2023en
dc.identifier.citationGianoukakis AG, Arnold SM, Kahn SA, Taylor M, Garralda E, Krebs MG, et al. A modular, open-label, phase I/II study to evaluate the safety, tolerability, pharmacokinetics and efficacy of EP0031, a next generation selective RET inhibitor, in patients with advanced RET-altered malignancies. Journal of Thoracic Oncology. 2023 Apr;18(4):S87-S8. PubMed PMID: WOS:000995007600083.en
dc.identifier.doi10.1016/S1556-0864(23)00336-2en
dc.identifier.urihttp://hdl.handle.net/10541/626402
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/S1556-0864(23)00336-2en
dc.titleA modular, open-label, phase I/II study to evaluate the safety, tolerability, pharmacokinetics and efficacy of EP0031, a next generation selective RET inhibitor, in patients with advanced RET-altered malignanciesen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentHarbor-UCLA Division of Endocrinology and Metabolism, The Lundquist Institute, Los Angeles, CA, USAen
dc.identifier.journalJournal of Thoracic Oncologyen
dc.description.noteen]


Files in this item

This item appears in the following Collection(s)

Show simple item record